Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 293,800 | 254,700 | 300,400 | 276,600 | 270,500 |
| Cost of Goods | 122,600 | 296,100 | 144,600 | 185,100 | 176,800 |
| Gross Profit | 171,200 | -41,400 | 155,800 | 91,500 | 93,700 |
| Operating Expenses | 107,300 | 162,200 | 116,600 | 135,400 | 336,600 |
| Operating Income | 64,500 | -203,500 | 39,800 | -43,800 | -242,100 |
| Interest Expense | 8,300 | 23,600 | 24,300 | 21,700 | 19,700 |
| Other Income | 86,200 | -42,700 | -3,400 | 11,000 | -4,100 |
| Pre-tax Income | 142,400 | -269,800 | 12,100 | -54,500 | -265,900 |
| Income Tax | 27,600 | 13,300 | 3,100 | -5,000 | -2,500 |
| Net Income Continuous | 114,800 | -283,100 | 9,000 | -49,500 | -263,400 |
| Net Income | $114,800 | $-283,100 | $9,000 | $-49,500 | $-263,400 |
| EPS Basic Total Ops | 2.16 | -5.38 | 0.17 | -0.90 | -5.08 |
| EPS Basic Continuous Ops | 2.16 | -5.38 | 0.17 | -0.90 | -5.08 |
| EPS Diluted Total Ops | 2.06 | -5.38 | 0.17 | -0.90 | -5.08 |
| EPS Diluted Continuous Ops | 2.06 | -5.38 | 0.17 | -0.90 | -5.08 |
| EPS Diluted Before Non-Recurring Items | 1.37 | -2.32 | 0.59 | N/A | N/A |
| EBITDA(a) | $84,200 | $-170,000 | $74,600 | $-8,500 | $9,800 |